Lu et al. showed that lorlatinib inhibited the proliferation of ALK-positive H3122 and H2228 NSCLC cells, as evidenced by their reduced clonogenic potential and precipitation of apoptosis [64]. This evidence concerns the gene ALK and non-small cell lung carcinoma.